Literature DB >> 17057757

Evidence that corticotropin-releasing factor receptor type 1 couples to Gs- and Gi-proteins through different conformations of its J-domain.

H Berger1, N Heinrich, D Wietfeld, M Bienert, M Beyermann.   

Abstract

BACKGROUND AND
PURPOSE: According to the two-domain model for the corticotropin-releasing factor receptor type 1 (CRF(1)), peptide antagonists bind to the N-terminal domain (N-domain), non-peptide antagonists to the transmembrane region (J-domain), whereas peptide agonists attach to both the N- and J-domain of the receptor to express activity. The aim of this study was to search for possible differences in the antagonism of the Gs- and Gi-protein coupling of CRF(1) by a peptide (alpha-helical CRF(9-41)) and non-peptide antagonist (antalarmin), to determine whether the conformational requirements of the activated CRF(1) states for Gs and Gi coupling are similar or different. EXPERIMENTAL APPROACH: We studied the inhibitory effect of alpha-helical CRF(9-41) and antalarmin on the coupling of CRF(1) to Gs- and Gi-protein in human embryonic kidney cells, using the [(35)S]-GTPgammaS binding stimulation assay. KEY
RESULTS: The non-peptide antagonized the receptor coupling to Gs competitively but that to Gi noncompetitively, and its antagonistic potency was different for urocortin- and sauvagine-evoked G-protein activation. In contrast, the peptide antagonist exhibited uniformly competitive antagonism. CONCLUSIONS AND IMPLICATIONS: The results allow us to extend the two-domain model of CRF(1) activation by assuming that CRF(1) agonists activate the receptor by binding to at least two ensembles of J-domain configurations which couple to Gs or Gi, that are in turn antagonized by a non-peptide antagonist competitively and allosterically, respectively. It is further concluded that the allosteric mechanism of non-peptide antagonism is not valid for the Gs-mediated physiological activities of CRF(1).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17057757      PMCID: PMC2014684          DOI: 10.1038/sj.bjp.0706926

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  20 in total

1.  A novel spliced variant of the type 1 corticotropin-releasing hormone receptor with a deletion in the seventh transmembrane domain present in the human pregnant term myometrium and fetal membranes.

Authors:  D K Grammatopoulos; Y Dai; H S Randeva; M A Levine; E Karteris; A J Easton; E W Hillhouse
Journal:  Mol Endocrinol       Date:  1999-12

Review 2.  G protein-coupled receptor allosterism and complexing.

Authors:  Arthur Christopoulos; Terry Kenakin
Journal:  Pharmacol Rev       Date:  2002-06       Impact factor: 25.468

3.  Constitutive activation of tethered-peptide/corticotropin-releasing factor receptor chimeras.

Authors:  S M Nielsen; L Z Nielsen; S A Hjorth; M H Perrin; W W Vale
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

4.  Mechanism of corticotropin-releasing factor type I receptor regulation by nonpeptide antagonists.

Authors:  Sam R J Hoare; Sue K Sullivan; Nicholas Ling; Paul D Crowe; Dimitri E Grigoriadis
Journal:  Mol Pharmacol       Date:  2003-03       Impact factor: 4.436

5.  GRK3 regulation during CRF- and urocortin-induced CRF1 receptor desensitization.

Authors:  Frank M Dautzenberg; Sandra Wille; Sandra Braun; Richard L Hauger
Journal:  Biochem Biophys Res Commun       Date:  2002-11-01       Impact factor: 3.575

Review 6.  Efficacy at G-protein-coupled receptors.

Authors:  Terry Kenakin
Journal:  Nat Rev Drug Discov       Date:  2002-02       Impact factor: 84.694

7.  Urocortin, but not corticotropin-releasing hormone (CRH), activates the mitogen-activated protein kinase signal transduction pathway in human pregnant myometrium: an effect mediated via R1alpha and R2beta CRH receptor subtypes and stimulation of Gq-proteins.

Authors:  D K Grammatopoulos; H S Randeva; M A Levine; E S Katsanou; E W Hillhouse
Journal:  Mol Endocrinol       Date:  2000-12

8.  Juxtamembrane region of the amino terminus of the corticotropin releasing factor receptor type 1 is important for ligand interaction.

Authors:  I Q Assil; L J Qi; M Arai; M Shomali; A B Abou-Samra
Journal:  Biochemistry       Date:  2001-02-06       Impact factor: 3.162

Review 9.  The CRF peptide family and their receptors: yet more partners discovered.

Authors:  Frank M Dautzenberg; Richard L Hauger
Journal:  Trends Pharmacol Sci       Date:  2002-02       Impact factor: 14.819

Review 10.  The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology.

Authors:  Edward W Hillhouse; Dimitris K Grammatopoulos
Journal:  Endocr Rev       Date:  2006-02-16       Impact factor: 19.871

View more
  16 in total

1.  Corticotropin-releasing factor and urocortin I activate CREB through functionally selective Gβγ signaling in hippocampal pyramidal neurons.

Authors:  Christopher M Stern; John Meitzen; Paul G Mermelstein
Journal:  Eur J Neurosci       Date:  2011-08-08       Impact factor: 3.386

2.  POU6f1 Mediates Neuropeptide-Dependent Plasticity in the Adult Brain.

Authors:  Cynthia K McClard; Mikhail Y Kochukov; Isabella Herman; Zhandong Liu; Aiden Eblimit; Yalda Moayedi; Joshua Ortiz-Guzman; Daniel Colchado; Brandon Pekarek; Sugi Panneerselvam; Graeme Mardon; Benjamin R Arenkiel
Journal:  J Neurosci       Date:  2018-01-05       Impact factor: 6.167

Review 3.  Insights into mechanisms of corticotropin-releasing hormone receptor signal transduction.

Authors:  Dimitris K Grammatopoulos
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

4.  Quantitative pharmacological analysis of antagonist binding kinetics at CRF1 receptors in vitro and in vivo.

Authors:  Simeon J Ramsey; Neil J Attkins; Rebecca Fish; Piet H van der Graaf
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 5.  Progress in corticotropin-releasing factor-1 antagonist development.

Authors:  Eric P Zorrilla; George F Koob
Journal:  Drug Discov Today       Date:  2010-03-03       Impact factor: 7.851

6.  Systemic urocortin 2, but not urocortin 1 or stressin 1-A, suppresses feeding via CRF2 receptors without malaise and stress.

Authors:  E M Fekete; Y Zhao; A Szücs; V Sabino; P Cottone; J Rivier; W W Vale; G F Koob; E P Zorrilla
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

7.  Achieving signalling selectivity of ligands for the corticotropin-releasing factor type 1 receptor by modifying the agonist's signalling domain.

Authors:  M Beyermann; N Heinrich; K Fechner; J Furkert; W Zhang; O Kraetke; M Bienert; H Berger
Journal:  Br J Pharmacol       Date:  2007-05-29       Impact factor: 8.739

8.  The role of PKC signaling in CRF-induced modulation of startle.

Authors:  M Toth; J E Gresack; R L Hauger; A L Halberstadt; V B Risbrough
Journal:  Psychopharmacology (Berl)       Date:  2013-05-31       Impact factor: 4.530

9.  Local CRH signaling promotes synaptogenesis and circuit integration of adult-born neurons.

Authors:  Isabella Garcia; Kathleen B Quast; Longwen Huang; Alexander M Herman; Jennifer Selever; Jan M Deussing; Nicholas J Justice; Benjamin R Arenkiel
Journal:  Dev Cell       Date:  2014-09-04       Impact factor: 12.270

10.  Receptor activity modifying proteins (RAMPs) interact with the VPAC2 receptor and CRF1 receptors and modulate their function.

Authors:  D Wootten; H Lindmark; M Kadmiel; H Willcockson; K M Caron; J Barwell; T Drmota; D R Poyner
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.